We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

143 hedge funds and large institutions have $435M invested in Sciclone Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 54 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

83% more capital inflows, than outflows

Capital inflows: $48.3M | Capital outflows: $26.4M

8% more funds holding

Funds holding: 133 → 143 (+10)

4.79% more ownership

Funds ownership: 74.87% → 79.65% (+4.8%)

15% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 54

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $324K

Holders
143
Holders Change
+10
Holders Change %
+7.52%
% of All Funds
3.8%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
26
Increased
46
Reduced
54
Closed
13
Calls
–
Puts
$324​K
Net Calls
-⁠$324​K
Net Calls Change
-⁠$390​K

SCLN Hedge Fund Activity: Q1 2016 in Review

143 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q1 2016, worth a combined $435M — up 27% from $342M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new SCLN positions and 13 closed out — a net gain of 13 holders — while 46 added to existing stakes and 54 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $12.9M. The largest seller was Morgan Stanley, cutting an estimated $3.24M.

  • 143 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q1 2016, up from 133 in Q4 2015.
  • Funds reported $435M of Sciclone Pharmaceuticals stock for Q1 2016, up 27% quarter-over-quarter.
  • 26 funds opened new Sciclone Pharmaceuticals positions in Q1 2016 and 13 closed out, a net change of +13 holders.
  • The largest Sciclone Pharmaceuticals buyer in Q1 2016 was Nantahala Capital Management, an estimated $12.9M added.
  • The largest Sciclone Pharmaceuticals seller in Q1 2016 was Morgan Stanley, an estimated $3.24M sold.

Based on aggregated 13F filings for Q1 2016.